GW PHARMACEUTICALS PLC Research and Development Expense
GW PHARMACEUTICALS PLC reported Research and Development Expense of $60.63 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-05-03
- GW PHARMACEUTICALS PLC research and development expense for the quarter ending 2021-03-31 was $60.63M, a 32.18% increase year-over-year.
- GW PHARMACEUTICALS PLC research and development expense for the quarter ending 2020-12-31 was $56.85M, a 30.59% increase year-over-year.
- GW PHARMACEUTICALS PLC research and development expense for the quarter ending 2020-09-30 was $56.93M, a 56.84% increase year-over-year.
- GW PHARMACEUTICALS PLC research and development expense for the quarter ending 2020-06-30 was $45.73M, a 40.86% increase year-over-year.
- GW PHARMACEUTICALS PLC research and development expense for fiscal 2020 was $205.40M, a 43.96% increase from fiscal 2019.
- GW PHARMACEUTICALS PLC research and development expense for fiscal 2019 was $142.68M.
- GW PHARMACEUTICALS PLC research and development expense for fiscal 2018 was $153.74M, a 36.96% increase from fiscal 2017.
- GW PHARMACEUTICALS PLC research and development expense for fiscal 2017 was $112.25M, a 7.54% increase from fiscal 2016.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2021-03-31 | $60.63M 10-Q · filed 2021-05-03 | $117.49M derived: sum of 2 quarters · filed 2021-05-03 | $174.42M derived: sum of 3 quarters · filed 2021-05-03 | $220.16M derived: sum of 4 quarters · filed 2021-05-03 |
| 2020-12-31 | $56.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $113.79M derived: sum of 2 quarters · filed 2021-02-26 | $159.52M derived: sum of 3 quarters · filed 2021-02-26 | $205.40M 10-K · filed 2021-02-26 |
| 2020-09-30 | $56.93M 10-Q · filed 2020-11-05 | $102.67M derived: sum of 2 quarters · filed 2020-11-05 | $148.54M 10-Q · filed 2020-11-05 | $192.08M derived: sum of 4 quarters · filed 2021-05-03 |
| 2020-06-30 | $45.73M 10-Q · filed 2020-08-07 | $91.61M 10-Q · filed 2020-08-07 | $135.14M derived: sum of 3 quarters · filed 2021-05-03 | $171.44M derived: sum of 4 quarters · filed 2021-05-03 |
| 2020-03-31 | $45.87M 10-Q · filed 2021-05-03 | $89.41M derived: sum of 2 quarters · filed 2021-05-03 | $125.71M derived: sum of 3 quarters · filed 2021-05-03 | $158.18M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $43.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $79.84M derived: sum of 2 quarters · filed 2021-02-26 | $112.30M derived: sum of 3 quarters · filed 2021-02-26 | $142.68M 10-K · filed 2021-02-26 |
| 2019-09-30 | $36.30M 10-Q · filed 2020-11-05 | $68.77M derived: sum of 2 quarters · filed 2020-11-05 | $99.14M 10-Q · filed 2020-11-05 | $128.23M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $32.47M 10-Q · filed 2020-08-07 | $62.84M 10-Q · filed 2020-08-07 | $91.93M derived: sum of 3 quarters · filed 2021-02-26 | $120.87M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $30.38M 10-Q · filed 2020-05-11 | $59.46M derived: sum of 2 quarters · filed 2021-02-26 | $88.40M derived: sum of 3 quarters · filed 2021-02-26 | $133.52M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $29.09M 10-K · filed 2021-02-26 | $58.03M derived: sum of 2 quarters · filed 2021-02-26 | $103.14M derived: sum of 3 quarters · filed 2021-02-26 | $146.63M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-09-30 | $28.94M 10-Q · filed 2019-11-06 | $74.06M derived: sum of 2 quarters · filed 2019-11-06 | $117.54M 10-Q · filed 2019-11-06 | $153.74M 10-K · filed 2021-02-26 |
| 2018-06-30 | $45.11M 10-Q · filed 2019-08-07 | $88.60M 10-Q · filed 2019-08-07 | $124.79M derived: sum of 3 quarters · filed 2021-02-26 | |
| 2018-03-31 | $43.48M 10-Q · filed 2019-05-08 | $79.68M derived: sum of 2 quarters · filed 2021-02-26 | ||
| 2017-12-31 | $36.20M 10-K · filed 2021-02-26 | |||
| 2017-09-30 | $112.25M 10-K · filed 2020-02-27 | |||
| 2016-09-30 | $104.38M 10-KT · filed 2019-02-28 |